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Disease Modifying Drugs for OA: 
from research to clinical 
evidence
OA treatments and limitations







Patient education, physical and
occupational Therapy, weight loss
Limitations
Costly, invasive procedure
Primarily indicated for «end stage » OA
GI bleeding or other complications
CV risks
Renalr complications






Disease-Osteoarthritis Modifying Drugs (DMOAD) is a category of






- Number of prothesis
Most popular candidate
-Glucosamine (GlcN) S or HCL
-Chondroïtin sulfate (CS)
-Unsaponifiable of Soybean/Avocado (ASU)
-Diacerein
Chondroitin sulfate Glucosamine sulfate/HCL
CS/GlcN: How do they work?







HARE or CD44 (HA)
GLcN/CS has a moderate effect on knee OA symptoms 
OARSI meta-analysis
(Zhang et al, 2010)
ES Pain ES Function
Acetominophen 0.14 (0.05,0.23) 0.09 (-0.03,0.22)
Diacerein 0.24 (0.08, 0.39) 0.14 (0.03, 0.26)
NSAIDs 0.29 (0.22,0.35) -
Aerobic 0.52 (0.34; 0.70) 0.46 (0.25, 067)
Glucosamine
Sulfate
0.58 (0,30, 0.87) 0.07 (-0.08,0,021)
Chondroitin sulfate 0.75 (0.50, 1.01) -
GAG effect size is superior to  NSAIDs with less GI adverse events
*All Studies
ES < 0.2 = None
ES 0.2 – 05 = Weak
ES 0.5 – 08 = Moderate
ES > 08 = Strong
versus placebo
at 1-4 weeks
GLcN/CS have a weak effect on disease 
modification   
 Chondroitin sulfate
Estimated Effect Size for reduction in rate of 
decline of minimum joint-space width (SMD): 
Ranges from 0.26 (0.14–0.38) to 0.30 (0.00–
0.59) WEAK
 Glucosamine sulfate 
Estimated Effect Size for reduction in rate of 
decline of minimum joint-space width (SMD): 
0.08 (−0.12–0.27) NONE
McAlindon et al. O&C 2014
Rationale to use GlcN or CS 
in OA treatment?
 Level of evidence : strong
 Quality of evidence: good
 Analgesic effect: moderate (> NSAIDS or 
Acetaminophen)
 Disease-modifying effect: None to weak 
(possible deleterious effect of NSAIDS)
 Safety : good (Severe adverse effect with 
NSAIDs)
BUT………
GLcN/CS in Recent Guidelines
Society recommendation
ACR 2012 Conditionally recommend that the 
patients with knee or hip OA 
should not use chondroitin sulfate 
or glucosamine
NICE 2013 Nutraceuticals: do not offer
glucosamine and chondroitin
products for the management of 
OA
OARSI 2014 « Uncertain » for symptoms relief
« Inappropriate » for structural 
effects
Why this reluctance for 
DMOAD?
 Lack of confidence in clinical trial?
 Geographical different practice?
 Inconsistency between industry-sponsored 
and independent studies?
 Heterogeneity among studies?
 Gap between expert opinion and real life?
 Cost of the treatment? Economical 
concern?
The risk 
« ….iatrogenesis  due to the overuse
NSAIDs, paracetamol and corticosteroids 
infiltration… »
Letter of the « Section arthrose » 
of  the french society of rheumatology to
CNEDIMTS
Conclusions
At least 2 good reasons to use DMOAD in 
OA:
- To control OA symptoms with a good safety
- To decrease NSAIDs consumption
But
 Evaluate DMOAD efficacy at individual level
 Stop treatment after 6 months if no clinical 
relevant pain effect
Thank you for your attention !
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